Skip to main content
Article thumbnail
Location of Repository

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension

By Peter Bramlage


Approximately 25% of the adult population worldwide is hypertensive and thus at risk of cardiovascular morbidity and mortality. Despite the availability of many antihypertensive drugs, at least 50% of patients do not achieve blood pressure (BP) targets and thus remain at increased cardiovascular risk. Fixed-dose (FD) irbesartan/hydrochlorothiazide (HCTZ) is an antihypertensive combination therapy approved for the treatment of patients whose BP is not adequately controlled on monotherapy and for initial treatment of patients likely to need multiple drugs to achieve their BP goal. The efficacy and tolerability of FD irbesartan/HCTZ has been demonstrated in both patient populations in large multicenter studies. In patients failing antihypertensive monotherapy, FD irbesartan/HCTZ (150/12.5 mg) has been shown to be more effective than FD valsartan/HCTZ (80/12.5 mg) and at least comparable to FD losartan/HCTZ (50/12.5 mg). In patients with moderate or severe hypertension receiving FD irbesartan/HCTZ as initial therapy, this combination achieved more rapid BP reductions compared with irbesartan monotherapy and enabled a greater proportion of patients with severe hypertension to achieve their BP target. FD irbesartan/HCTZ is thus a valuable addition to the clinician’s armamentarium for the management of hypertension and should help more patients achieve their BP target

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. MMW Fortschr Med.
  2. (2005). [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi.
  3. A comparison of the effi cacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
  4. A home blood pressure monitoring study comparing the antihypertensive effi cacy of two angiotensin II receptor antagonist fi xed combinations.
  5. Adherence patterns among patients treated with fi xed-dose combination versus separate antihypertensive agents.
  6. Age-specifi c relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
  7. Ambulatory blood pressure comparison of the anti-hypertensive effi cacy of fi xed combinations of irbesartan/ hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension.
  8. (2005). Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: a prospective, open-label study. Clin Drug Investig.
  9. Antihypertensive effi cacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
  10. (2004). Association. Standards of medical care in diabetes. Diabetes Care.
  11. (2007). Avalide prescribing information.
  12. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
  13. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
  14. (2007). BP goal achievement in patients with uncontrolled hypertension: results of the treat-to-target post-marketing survey with irbesartan. Clin Drug Investig.
  15. Clinical practice and recent recommendations in hypertension management – reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Current Medical Research and Opinions.
  16. (2007). CoAprovel summary of product characteristics.
  17. Compliance with antihypertensive therapy in the elderly: a comparison of fi xed-dose combination amlodipine/ benazepril versus component-based free-combination therapy.
  18. (1999). Compliance with antihypertensive therapy. Clin Exp Hypertens.
  19. (2006). Differences in glucose tolerance between fi xed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care.
  20. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population.
  21. (1997). Effect of hydrochlorothiazide on the pharmacokinetics and pharmadodynamics of angiotensin II blocker irbesartan. Drug Invest.
  22. (2005). Effect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients. Curr Med Res Opin.
  23. (2008). Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int.
  24. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
  25. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
  26. Effi cacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
  27. Effi cacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
  28. Effi cacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
  29. (2008). facts and fi gures. World Health Organization.
  30. Fixed-dose combination improves medication compliance.
  31. Global burden of hypertension: analysis of worldwide data.
  32. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
  33. Hypertension treatment and control in fi ve European countries, Canada, and the United States.
  34. (2007). Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy. J Clin Hypertens (Greenwich).
  35. (2007). Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol.
  36. Irbesartan/HCTZ fi xed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
  37. (2008). Irbesartan/hydrochlorothiazide as initial therapy: subanalysis in patients with systolic
  38. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.
  39. (1999). Long-term safety and antihypertensive effi cacy of irbesartan: pooled results of fi ve open-label studies. Clin Exp Hypertens.
  40. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens.
  41. Olmesartan for the treatment of arterial hypertension.
  42. (2003). Once-daily fi xed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profi le in patients with essential hypertension. Clin Ther.
  43. (2007). Outpatient hypertension treatment, treatment intensifi cation, and control in Western Europe and the United States. Arch Intern Med.
  44. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects.
  45. (2003). Practice guidelines for primary care physicians:
  46. Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.
  47. (2001). Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on
  48. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
  49. Systolic and diastolic blood pressure control in antihypertensive drug trials.
  50. Systolic pressure is all that matters.
  51. (2008). The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial effi cacy and safety study. Clin Ther.
  52. (1994). The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care.
  53. The effi -cacy and safety of initial use of irbesartan/hydrochlorothiazide fi xed-dose combination in hypertensive patients with and without high cardiovascular risk. J Clin Hypertens (Greenwich).
  54. The effi cacy and safety of initial use of irbesartan/hydrochlorothiazide fi xed-dose combination in hypertensive patients with and without high cardiovascular risk. J Clin Hypertens (Greenwich).
  55. The effi cacy and safety of low- and high-dose fi xed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
  56. (1999). The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens.
  57. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.